drugset
Drugs / Recombinant Interferon Beta
last change Dec 2018 re-read 3 minutes ago

Recombinant Interferon Beta

Protein / enzyme biologic

Developed for
cutaneous neuroendocrine carcinoma
Investigated by
Fred Hutchinson Cancer Center · National Cancer Institute (NCI) · EMD Serono

Trials 2

today NCT02584829 · Ph 1/2 NCT01758458 · Ph 1/2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02584829 Nov 2015 → Dec 2018 — Fred Hutchinson Cancer Center Terminated No outcome recorded Stop: Business
Phase 1/2 NCT01758458 Feb 2013 → May 2016 cutaneous neuroendocrine carcinoma Fred Hutchinson Cancer Center Terminated No outcome recorded Stop: Enrollment

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Recombinant Interferon Beta ClinicalTrials.gov intervention name — accepted as the source's own label NCT02584829 ↗
1

NCT01758458 ↗
Modality Protein / enzyme biologic “recombinant interferon beta” NCT01758458 ↗
Route Other “Given intralesionally” NCT01758458 ↗